CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges
Patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have poor prognosis with a high unmet need for efficacious treatment options. Most patients with r/r large B-cell lymphoma (LBCL) are elderly, which adds to the complexity of choosing the appropriate and effective therapy...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/6/e009793.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850224976901177344 |
|---|---|
| author | Matthew J Frigault Peter A Riedell Leyla Shune |
| author_facet | Matthew J Frigault Peter A Riedell Leyla Shune |
| author_sort | Matthew J Frigault |
| collection | DOAJ |
| description | Patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have poor prognosis with a high unmet need for efficacious treatment options. Most patients with r/r large B-cell lymphoma (LBCL) are elderly, which adds to the complexity of choosing the appropriate and effective therapy in these patients. Recently approved therapies, such as CD19-targeted chimeric antigen receptor-T cell therapy, have shown improvements in the outcomes of patients with r/r DLBCL. Several real-world studies also support the use of these newer therapies in elderly patients. However, given the frailty, variability in the risk factors in each elderly patient, and the increased susceptibility for adverse events, a comprehensive geriatric assessment and a multidisciplinary approach could be helpful in guiding the management and treatment choices for these vulnerable patients. Individualized care can aid in giving elderly patients with r/r LBCL the best possible outcome with their chosen treatment regimen. |
| format | Article |
| id | doaj-art-c58355a6ca6c402984430a5659fea4e6 |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-c58355a6ca6c402984430a5659fea4e62025-08-20T02:05:29ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-06-0113610.1136/jitc-2024-009793CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challengesMatthew J Frigault0Peter A Riedell1Leyla Shune2Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USAThe David and Etta Jonas Center for Cellular Therapy, University of Chicago Biological Sciences Division, Chicago, Illinois, USADivision of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas, USAPatients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have poor prognosis with a high unmet need for efficacious treatment options. Most patients with r/r large B-cell lymphoma (LBCL) are elderly, which adds to the complexity of choosing the appropriate and effective therapy in these patients. Recently approved therapies, such as CD19-targeted chimeric antigen receptor-T cell therapy, have shown improvements in the outcomes of patients with r/r DLBCL. Several real-world studies also support the use of these newer therapies in elderly patients. However, given the frailty, variability in the risk factors in each elderly patient, and the increased susceptibility for adverse events, a comprehensive geriatric assessment and a multidisciplinary approach could be helpful in guiding the management and treatment choices for these vulnerable patients. Individualized care can aid in giving elderly patients with r/r LBCL the best possible outcome with their chosen treatment regimen.https://jitc.bmj.com/content/13/6/e009793.full |
| spellingShingle | Matthew J Frigault Peter A Riedell Leyla Shune CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges Journal for ImmunoTherapy of Cancer |
| title | CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges |
| title_full | CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges |
| title_fullStr | CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges |
| title_full_unstemmed | CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges |
| title_short | CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges |
| title_sort | car t cell therapy in older adults with relapsed refractory lbcl benefits and challenges |
| url | https://jitc.bmj.com/content/13/6/e009793.full |
| work_keys_str_mv | AT matthewjfrigault cartcelltherapyinolderadultswithrelapsedrefractorylbclbenefitsandchallenges AT peterariedell cartcelltherapyinolderadultswithrelapsedrefractorylbclbenefitsandchallenges AT leylashune cartcelltherapyinolderadultswithrelapsedrefractorylbclbenefitsandchallenges |